DiaMedica Therapeutics Inc. (DMAC)
After hours:
| Previous close | 3.6900 |
| Open | 3.7400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6100 - 3.7400 |
| 52-week range | 1.9382 - 3.8056 |
| Volume | |
| Avg. volume | 62,680 |
| Market cap | 155.582M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
Simply Wall St.DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39%
Key Insights Significant control over DiaMedica Therapeutics by individual investors implies that the general public...
Business WireDiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
MINNEAPOLIS, July 11, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.
Business WireDiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
MINNEAPOLIS, July 01, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximately 4.7 million common shares at a purchase price of $2.50 per share, a premium of approximately 10% above the Company’s per share closing price on Tuesday June 25, 2024. After
